Cargando…

A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced Gastric Cancer

Introduction: No effective peripheral blood predictors have been establoshed for first-line chemotherapy in patients with advanced gastric cancer. In this study, a nomogram combining the neutrophil-to-lymphocyte ratio/D-dimer with gender, number of metastases, and histological grade was established...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Hao, Wu, Shusheng, Su, Rixin, Chen, Yaolin, He, Yifu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340318/
https://www.ncbi.nlm.nih.gov/pubmed/35880288
http://dx.doi.org/10.1177/15330338221112741
_version_ 1784760375359569920
author Shen, Hao
Wu, Shusheng
Su, Rixin
Chen, Yaolin
He, Yifu
author_facet Shen, Hao
Wu, Shusheng
Su, Rixin
Chen, Yaolin
He, Yifu
author_sort Shen, Hao
collection PubMed
description Introduction: No effective peripheral blood predictors have been establoshed for first-line chemotherapy in patients with advanced gastric cancer. In this study, a nomogram combining the neutrophil-to-lymphocyte ratio/D-dimer with gender, number of metastases, and histological grade was established to predict progression-free survival in patients with unresectable advanced gastric cancer. Methods: We retrospectively collected baseline clinical characteristics and blood parameters from 153 patients diagnosed with advanced gastric cancer that underwent oxaliplatin-based first-line chemotherapy. Kaplan–Meier analysis and Cox regression analysis were used to determine the factors associated with progression-free survival. The concordance index (C-index) and calibration curve were used to determine the prediction accuracy and discriminative ability of the nomogram as a visual complement to the prognostic score system. Results: Determined by the X-tile software, the optimal cut-off points for the neutrophil-to-lymphocyte ratio and D-dimer were 3.18 and 0.56 mg/L, respectively. Multivariate analysis identified four independent prognostic factors: two or more metastatic organs (HR: 1.562, 95% CI: 1.009-2.418, P = .046), poor differentiation (HR: 0.308, 95% CI: 0.194-0.487, P < .001), neutrophil-to-lymphocyte ratio >3.18 (HR: 1.427, 95% CI: 1.024-1.989, P = .036), and D-dimer >0.56 mg/L (HR: 1.811, 95% CI: 1.183-2.773, P = .006). Receiver operating characteristic curves showed that the combination of the neutrophil-to-lymphocyte ratio and D-dimer in the prediction model exhibited the highest predictive performance (area under the curve, 0.800). The prognostic nomogram yielded a C-index of 0.800. Decision curve analysis demonstrated that the prognostic nomogram was clinically useful. A nomogram-based risk classification system was also constructed to facilitate risk stratification of advanced gastric cancer for optimal clinical management. Conclusion: We identified the neutrophil-to-lymphocyte ratio and D-dimer level as independent prognostic factors for advanced gastric cancer. The prognostic nomogram combining the neutrophil-to-lymphocyte ratio and D-dimer level can be applied in the individualized prediction of treatment outcome in patients with advanced gastric cancer.
format Online
Article
Text
id pubmed-9340318
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-93403182022-08-02 A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced Gastric Cancer Shen, Hao Wu, Shusheng Su, Rixin Chen, Yaolin He, Yifu Technol Cancer Res Treat Original Article Introduction: No effective peripheral blood predictors have been establoshed for first-line chemotherapy in patients with advanced gastric cancer. In this study, a nomogram combining the neutrophil-to-lymphocyte ratio/D-dimer with gender, number of metastases, and histological grade was established to predict progression-free survival in patients with unresectable advanced gastric cancer. Methods: We retrospectively collected baseline clinical characteristics and blood parameters from 153 patients diagnosed with advanced gastric cancer that underwent oxaliplatin-based first-line chemotherapy. Kaplan–Meier analysis and Cox regression analysis were used to determine the factors associated with progression-free survival. The concordance index (C-index) and calibration curve were used to determine the prediction accuracy and discriminative ability of the nomogram as a visual complement to the prognostic score system. Results: Determined by the X-tile software, the optimal cut-off points for the neutrophil-to-lymphocyte ratio and D-dimer were 3.18 and 0.56 mg/L, respectively. Multivariate analysis identified four independent prognostic factors: two or more metastatic organs (HR: 1.562, 95% CI: 1.009-2.418, P = .046), poor differentiation (HR: 0.308, 95% CI: 0.194-0.487, P < .001), neutrophil-to-lymphocyte ratio >3.18 (HR: 1.427, 95% CI: 1.024-1.989, P = .036), and D-dimer >0.56 mg/L (HR: 1.811, 95% CI: 1.183-2.773, P = .006). Receiver operating characteristic curves showed that the combination of the neutrophil-to-lymphocyte ratio and D-dimer in the prediction model exhibited the highest predictive performance (area under the curve, 0.800). The prognostic nomogram yielded a C-index of 0.800. Decision curve analysis demonstrated that the prognostic nomogram was clinically useful. A nomogram-based risk classification system was also constructed to facilitate risk stratification of advanced gastric cancer for optimal clinical management. Conclusion: We identified the neutrophil-to-lymphocyte ratio and D-dimer level as independent prognostic factors for advanced gastric cancer. The prognostic nomogram combining the neutrophil-to-lymphocyte ratio and D-dimer level can be applied in the individualized prediction of treatment outcome in patients with advanced gastric cancer. SAGE Publications 2022-07-25 /pmc/articles/PMC9340318/ /pubmed/35880288 http://dx.doi.org/10.1177/15330338221112741 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Shen, Hao
Wu, Shusheng
Su, Rixin
Chen, Yaolin
He, Yifu
A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced Gastric Cancer
title A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced Gastric Cancer
title_full A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced Gastric Cancer
title_fullStr A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced Gastric Cancer
title_full_unstemmed A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced Gastric Cancer
title_short A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced Gastric Cancer
title_sort nomogram combining neutrophil-to-lymphocyte ratio and d-dimer predicts chemosensitivity of oxaliplatin-based first-line chemotherapy in patients with unresectable advanced gastric cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340318/
https://www.ncbi.nlm.nih.gov/pubmed/35880288
http://dx.doi.org/10.1177/15330338221112741
work_keys_str_mv AT shenhao anomogramcombiningneutrophiltolymphocyteratioandddimerpredictschemosensitivityofoxaliplatinbasedfirstlinechemotherapyinpatientswithunresectableadvancedgastriccancer
AT wushusheng anomogramcombiningneutrophiltolymphocyteratioandddimerpredictschemosensitivityofoxaliplatinbasedfirstlinechemotherapyinpatientswithunresectableadvancedgastriccancer
AT surixin anomogramcombiningneutrophiltolymphocyteratioandddimerpredictschemosensitivityofoxaliplatinbasedfirstlinechemotherapyinpatientswithunresectableadvancedgastriccancer
AT chenyaolin anomogramcombiningneutrophiltolymphocyteratioandddimerpredictschemosensitivityofoxaliplatinbasedfirstlinechemotherapyinpatientswithunresectableadvancedgastriccancer
AT heyifu anomogramcombiningneutrophiltolymphocyteratioandddimerpredictschemosensitivityofoxaliplatinbasedfirstlinechemotherapyinpatientswithunresectableadvancedgastriccancer
AT shenhao nomogramcombiningneutrophiltolymphocyteratioandddimerpredictschemosensitivityofoxaliplatinbasedfirstlinechemotherapyinpatientswithunresectableadvancedgastriccancer
AT wushusheng nomogramcombiningneutrophiltolymphocyteratioandddimerpredictschemosensitivityofoxaliplatinbasedfirstlinechemotherapyinpatientswithunresectableadvancedgastriccancer
AT surixin nomogramcombiningneutrophiltolymphocyteratioandddimerpredictschemosensitivityofoxaliplatinbasedfirstlinechemotherapyinpatientswithunresectableadvancedgastriccancer
AT chenyaolin nomogramcombiningneutrophiltolymphocyteratioandddimerpredictschemosensitivityofoxaliplatinbasedfirstlinechemotherapyinpatientswithunresectableadvancedgastriccancer
AT heyifu nomogramcombiningneutrophiltolymphocyteratioandddimerpredictschemosensitivityofoxaliplatinbasedfirstlinechemotherapyinpatientswithunresectableadvancedgastriccancer